Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 45

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 45
---
 an incident. As an early-stage
company without significant investments in data security protection, we may not be sufficiently protected against such occurrences. We
also lack sufficient resources to adequately protect against, or to investigate and remediate any vulnerability to, cyber incidents.
It is possible that any of these occurrences, or a combination of them, could have material adverse consequences on our business and
lead to financial loss. We have established certain processes for identifying, evaluating, and managing material risks from cybersecurity
threats as a part of our overall technology management strategy. These processes are designed and reassessed on a periodic basis to help
protect our technology assets and operations from internal and external security threats.

Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.

On
January 29, 2025, we consummated the Initial Public Offering of 20,000,000 Units at $10.00 per Unit, generating proceeds of $200,000,000.
Clear Street LLC acted as sole book-running manager of the Initial Public Offering. The securities in the offering were registered under
the Securities Act on registration statement on Form S-1 (No. 333-281170). The registration statement was declared effective on January
7, 2025 and the post-effective amendment to the registration statement was declared effective on January 27, 2025.

Simultaneous
with the consummation of the Initial Public Offering, we consummated the private placement with the sponsor of 400,000 Private Placement
Units at a price of $10.00 per unit, generating total proceeds of $4,000,000. Each Private Placement Unit consists of one ordinary share
and one right to receive one-eighth (1/8) of one ordinary share upon the consummation of an initial business combination. The proceeds
from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the trust account.
The issuance was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

On
February 18, 2025, the underwriters exercised their over-allotment option to purchase an additional 3,000,000 Units at a purchase price
of $10.00 per Unit, generating additional gross proceeds of $30,000,000. In connection with the underwriters’ exercise of their
over-allotment option, the Company also consummated the sale of an additional 30,000 Private Placement